High Free Cash Flow Stocks
PTCT is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
PTC THERAPEUTICS INC (PTCT) Stock Price & Overview
NASDAQ:PTCT • US69366J2006
Current stock price
73.01 USD
+2.59 (+3.68%)
At close:
72.8883 USD
-0.12 (-0.17%)
After Hours:
The current stock price of PTCT is 73.01 USD. Today PTCT is up by 3.68%. In the past month the price increased by 9.44%. In the past year, price increased by 54.06%.
PTCT Key Statistics
52-Week Range35.95 - 87.5
Current PTCT stock price positioned within its 52-week range.
1-Month Range64 - 73.79
Current PTCT stock price positioned within its 1-month range.
- Market Cap
- 6.043B
- P/E
- 9.43
- Fwd P/E
- N/A
- EPS (TTM)
- 7.74
- Dividend Yield
- N/A
PTCT Stock Performance
Today
+3.68%
1 Week
+4.93%
1 Month
+9.44%
3 Months
+0.73%
Longer-term
6 Months +10.71%
1 Year +54.06%
2 Years +127.09%
3 Years +32.41%
5 Years +77.17%
10 Years +883.96%
PTCT Stock Chart
PTCT Stock Screens
PTCT currently appears in the following ChartMill screener lists.
Fastest Growing Stocks
PTCT is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
PTCT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PTCT. When comparing the yearly performance of all stocks, PTCT is one of the better performing stocks in the market, outperforming 80.09% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
PTCT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PTCT. PTCT has an average financial health and profitability rating.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PTCT Earnings
On February 19, 2026 PTCT reported an EPS of -1.67 and a revenue of 213.20M. The company missed EPS expectations (-4466.01% surprise) and missed revenue expectations (-24.45% surprise).
Next Earnings DateApr 23, 2026
Last Earnings DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported-$1.67
Revenue Reported213.2M
EPS Surprise -4,466.01%
Revenue Surprise -24.45%
PTCT Forecast & Estimates
21 analysts have analysed PTCT and the average price target is 87.79 USD. This implies a price increase of 20.24% is expected in the next year compared to the current price of 73.01.
For the next year, analysts expect an EPS growth of -110.07% and a revenue growth -46.89% for PTCT
Analysts
Analysts76.19
Price Target87.79 (20.24%)
EPS Next Y-110.07%
Revenue Next Year-46.89%
PTCT Groups
Sector & Classification
PTCT Financial Highlights
Over the last trailing twelve months PTCT reported a non-GAAP Earnings per Share(EPS) of 7.74. The EPS increased by 228.79% compared to the year before.
Income Statements
Revenue(TTM)1.73B
Net Income(TTM)682.64M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 39.44% | ||
| ROA | 23.55% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%22.33%
Sales Q2Q%0.01%
EPS 1Y (TTM)228.79%
Revenue 1Y (TTM)114.51%
PTCT Ownership
Ownership
Inst Owners113.34%
Shares82.77M
Float76.45M
Ins Owners0.84%
Short Float %12.36%
Short Ratio8.37
PTCT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.18 | 365.196B | ||
| AMGN | AMGEN INC | 15.37 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.89 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.72 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 11.1 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.79 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.62 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PTCT
Company Profile
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 991 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Company Info
IPO: 2013-06-20
PTC THERAPEUTICS INC
500 Warren Corporate Center Drive
WARREN NEW JERSEY 07080 US
CEO: Stuart W. Peltz
Employees: 991
Phone: 13026365400
PTC THERAPEUTICS INC / PTCT FAQ
What does PTC THERAPEUTICS INC do?
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 991 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
What is the current price of PTCT stock?
The current stock price of PTCT is 73.01 USD. The price increased by 3.68% in the last trading session.
Does PTCT stock pay dividends?
PTCT does not pay a dividend.
How is the ChartMill rating for PTC THERAPEUTICS INC?
PTCT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the market expecting PTCT stock to perform?
21 analysts have analysed PTCT and the average price target is 87.79 USD. This implies a price increase of 20.24% is expected in the next year compared to the current price of 73.01.
Can you provide the growth outlook for PTC THERAPEUTICS INC?
The Revenue of PTC THERAPEUTICS INC (PTCT) is expected to decline by -46.89% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for PTCT stock?
PTC THERAPEUTICS INC (PTCT) will report earnings on 2026-04-23, after the market close.